Bristol-Myers Squibb, Pharmacyclics and Janssen team up to test Opdivo and Imbruvica combination

13 October 2014

US drug major Bristol-Myers Squibb (NYSE: BMY), USA-based biopharma company Pharmacyclics (Nasdaq: PCYC) and Janssen Research and Development, the Europe-based subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ) have entered into a clinical trial collaboration agreement to evaluate B-MS’ Opdivo (nivolumab) in combination with Imbruvica (ibrutinib).

Imbruvica is an oral Bruton’s tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen, and is being evaluated alongside the PD-1 immune checkpoint inhibitor Opdivo in the treatment of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia.

Opdivo/Imbruvica in hematologic malignancies

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK